Phase 3Not yet recruitingAge-related condition
Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia
A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of UROCOM-R1 Plus UROCOM-R2 Combination Therapy Versus UROCOM-R1 or UROCOM-R2 Monotherapy in Patients With Benign Prostatic Hyperplasia
- Sponsor
- Il-Yang Pharm. Co., Ltd. (Industry)
- Enrolment
- 660 planned
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Finasteride 5 mg Tablet, single dose; Tamsulosin 0.4Mg Capsule
- Ages
- adults, older adults
- Registry
- NCT07870759
Full record on ClinicalTrials.gov
From the registry
Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia
Primary outcomes
- Total IPSS
History
Primary completion expected
Expected to start
Registered